InflaRx Statistics
Total Valuation
InflaRx has a market cap or net worth of $247.58 million. The enterprise value is $67.43 million.
| Market Cap | 247.58M |
| Enterprise Value | 67.43M |
Important Dates
The next estimated earnings date is Monday, November 9, 2026, before market open.
| Earnings Date | Nov 9, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
InflaRx has 147.37 million shares outstanding. The number of shares has increased by 31.84% in one year.
| Current Share Class | 147.37M |
| Shares Outstanding | 147.37M |
| Shares Change (YoY) | +31.84% |
| Shares Change (QoQ) | +62.76% |
| Owned by Insiders (%) | 2.95% |
| Owned by Institutions (%) | 39.91% |
| Float | 98.11M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | -21,453.95 |
| Forward PS | n/a |
| PB Ratio | 1.52 |
| P/TBV Ratio | 1.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 8.22, with a Debt / Equity ratio of 0.01.
| Current Ratio | 8.22 |
| Quick Ratio | 7.95 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -582.09 |
Financial Efficiency
Return on equity (ROE) is -38.52% and return on invested capital (ROIC) is -21.78%.
| Return on Equity (ROE) | -38.52% |
| Return on Assets (ROA) | -18.54% |
| Return on Invested Capital (ROIC) | -21.78% |
| Return on Capital Employed (ROCE) | -24.29% |
| Weighted Average Cost of Capital (WACC) | 18.52% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$688,021 |
| Employee Count | 65 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, InflaRx has paid $14,032 in taxes.
| Income Tax | 14,032 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +6.33% in the last 52 weeks. The beta is 2.60, so InflaRx's price volatility has been higher than the market average.
| Beta (5Y) | 2.60 |
| 52-Week Price Change | +6.33% |
| 50-Day Moving Average | 1.99 |
| 200-Day Moving Average | 1.59 |
| Relative Strength Index (RSI) | 31.09 |
| Average Volume (20 Days) | 494,674 |
Short Selling Information
The latest short interest is 12.11 million, so 8.96% of the outstanding shares have been sold short.
| Short Interest | 12.11M |
| Short Previous Month | 12.30M |
| Short % of Shares Out | 8.96% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 15.09 |
Income Statement
In the last 12 months, InflaRx had revenue of -$11,540 and -$44.72 million in losses. Loss per share was -$0.54.
| Revenue | -11,540 |
| Gross Profit | -5.56M |
| Operating Income | -40.73M |
| Pretax Income | -44.71M |
| Net Income | -44.72M |
| EBITDA | -40.72M |
| EBIT | -40.73M |
| Loss Per Share | -$0.54 |
Balance Sheet
The company has $181.10 million in cash and $951,878 in debt, with a net cash position of $180.15 million or $1.22 per share.
| Cash & Cash Equivalents | 181.10M |
| Total Debt | 951,878 |
| Net Cash | 180.15M |
| Net Cash Per Share | $1.22 |
| Equity (Book Value) | 167.01M |
| Book Value Per Share | 1.13 |
| Working Capital | 165.97M |
Cash Flow
In the last 12 months, operating cash flow was -$26.58 million and capital expenditures -$152,404, giving a free cash flow of -$26.73 million.
| Operating Cash Flow | -26.58M |
| Capital Expenditures | -152,404 |
| Depreciation & Amortization | 13,082 |
| Net Borrowing | -346,657 |
| Free Cash Flow | -26.73M |
| FCF Per Share | -$0.18 |
Margins
| Gross Margin | n/a |
| Operating Margin | 352,966.34% |
| Pretax Margin | 387,411.93% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
InflaRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -31.84% |
| Shareholder Yield | -31.84% |
| Earnings Yield | -18.06% |
| FCF Yield | -10.80% |
Analyst Forecast
The average price target for InflaRx is $7.68, which is 357.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.68 |
| Price Target Difference | 357.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
InflaRx has an Altman Z-Score of -0.14 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -0.14 |
| Piotroski F-Score | 3 |